Canaccord analyst William Plovanic raised the firm’s price target on Boston Scientific to $64 from $60 and keeps a Buy rating on the shares. The firm updated its model following its acquisition of Relievant which caused them to raise their revenue estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BSX:
- Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.
- Boston Scientific sees Relievant acquisition ‘slightly accretive’ to EPS in 2025
- Early notable gainers among liquid option names on November 13th
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific price target lowered to $60 from $64 at Canaccord